CanSino Biologics Inc. (FRA:CJH)

Germany flag Germany · Delayed Price · Currency is EUR
3.916
-0.116 (-2.88%)
Last updated: Jan 28, 2026, 3:25 PM CET
17.95%
Market Cap1.46B +9.8%
Revenue (ttm)116.35M +29.8%
Net Income-17.00M
EPS-0.07
Shares Outn/a
PE Ration/a
Forward PE52.77
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume870
Open3.882
Previous Close4.032
Day's Range3.882 - 3.916
52-Week Range3.120 - 6.000
Betan/a
RSI41.92
Earnings DateMar 5, 2026

About CanSino Biologics

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People’s Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. In addition, it develops Tdcp Adolescent ... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2009
Employees 1,115
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol CJH
Full Company Profile

Financial Performance

In 2024, CanSino Biologics's revenue was 846.34 million, an increase of 137.01% compared to the previous year's 357.08 million. Losses were -378.88 million, -74.45% less than in 2023.

Financial numbers in CNY Financial Statements